Pain Therapeutics Receives Complete Response Letter From FDA For REMOXY(R) DURECT Corporation (Nasdaq: DRRX) reported that Pain Therapeutics, Inc. (Nasdaq: PTIE) has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for REMOXY(R), an abuse-resistant controlled-release form of oxycodone. Based on its review, the FDA has determined that the NDA is not approved in its present form. According to King Pharmaceuticals, Inc.
Source: www.medicalnewstoday.com
# posted by Network @ 5:00 AM
